Marken opens new GDP-compliant facility

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/hxdyl)
(Image: iStock/hxdyl)

Related tags: Service, Pharmacology

The recently expanded and relocated GDP-compliant facility will operate 24/7/365 and is located in Zurich, Switzerland. 

The new site replaces a smaller office and expands the company’s capabilities in response to a growing demand from local companies with clinical development programs.

Frederic Maurice, regional director at Marken told the expansion is due to “growth of our main pharma clients in Switzerland and the growth of our temperature controlled drug shipments with passive packaging solutions.”

Maurice said the company’s main demand is in temperature controlled drug shipments, direct to patient services, and Cell and Gene Therapy supply chain services.

The facility includes office and warehouse space with refrigerators and freezers for temperature controlled packaging. It is also connected to Marken's global 'Maestro' operating system and conforms to the Swiss Minergie (green) standard, a registered quality label for new and refurbished low-energy-consumption buildings.

The new facility will have an expanded warehouse, a larger customer service team and will be equipped with new flat screens to monitor in real time our drug shipments through our exclusive GPS tracker Sentry​,” added Maurice.

Marken previously announced​ an expansion of its third party service providers and customs brokers network to prepare for a "significant​" increase in drug, vaccine, API, and ancillary shipment volumes.

Related news

Show more

Related products

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more